Preliminary transcriptomic signatures suggested that CD68, CD163, and SPP1 may serve as potential biomarkers for AL, offering a novel research perspective for future diagnosis and therapeutic intervention of AL. This evidence concerns the gene SPP1 and axial length measurement.